Clinical Trials
244 trialsUmbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
KEAP
Karyopharm Therapeutics Inc
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
City of Hope Medical Center
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
University of Michigan Rogel Cancer Center
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Vastra Gotaland Region
SANGUINE
JaxBio Ltd
The Microbiome in Blood Cancer and HLH
University of Nottingham
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Mustang Bio
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
City of Hope Medical Center
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
Rutgers, The State University of New Jersey
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Asana BioSciences
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Prelude Therapeutics
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
Roswell Park Cancer Institute
Collecting and Storing Blood Samples From Patients With Cancer
Rutgers, The State University of New Jersey
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
Northwestern University
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
MK-3475-013
Merck Sharp & Dohme LLC
CALVI
University Hospital, Clermont-Ferrand
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer
M.D. Anderson Cancer Center
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
Roswell Park Cancer Institute
Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter
Jonsson Comprehensive Cancer Center
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Jonsson Comprehensive Cancer Center
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
Case Comprehensive Cancer Center
Treatment for Chronic Pain in Patients With Advanced Cancer
Canadian Cancer Trials Group
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Fred Hutchinson Cancer Center
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison